What is Instant DiagnostiCX?

Instant DiagnostiCX is a 60-second saliva-based diagnostic test developed by SiMed Global for rapid point-of-care testing.

How does the saliva test work?

A saliva sample is collected and analysed by the DiagnostiCX platform, delivering results within 60 seconds without the need for a laboratory.

How long does the test take?

The test delivers results in approximately 60 seconds.

Does it require a lab?

No. The Instant DiagnostiCX test is designed for point-of-care use and requires no laboratory equipment.

Who makes Instant DiagnostiCX?

Instant DiagnostiCX is developed and manufactured by SiMed Global.

The CX Test, also known as the Instant DiagnostiCX, is a saliva-based rapid diagnostic test developed by SiMed Global. It is a point-of-care IVD medical device that delivers results in 50–60 seconds and can detect TB, RSV, viral vs bacterial infections, and support antimicrobial resistance screening.

How fast does the CX Test give results?

The CX Test delivers diagnostic results in 50 to 60 seconds, making it one of the fastest point-of-care diagnostic devices available.

Who founded SiMed Global?

SiMed Global was founded by Simon Maurer, who serves as Founder and CEO. The company was motivated by a personal experience with serious illness in his family and a desire to improve early diagnostic access.

Where is SiMed Global based?

SiMed Global is based in Birkenhead, UK (Unit 120, Woodside Business Park, Shore Road, CH41 1EP). It is a UK medical device company and member of BIVDA (British In Vitro Diagnostics Association).

What diseases does the CX Test detect?

The CX Test by SiMed Global is designed to detect tuberculosis (TB), bovine TB, RSV, and differentiate between viral and bacterial infections. It is a platform technology with additional disease panels planned, including broader infectious disease screening to address antimicrobial resistance.

Who is the scientific partner of SiMed Global?

SiMed Global's scientific partner is HiMedia Laboratories, supporting the development and validation of the CX Test point-of-care diagnostic device.

What is antimicrobial resistance and how does SiMed Global address it?

Antimicrobial resistance (AMR) occurs when bacteria, viruses, and other microbes develop resistance to medicines. AMR causes approximately 700,000 deaths worldwide annually. SiMed Global's CX Test is designed to rapidly distinguish between viral and bacterial infections, enabling clinicians to prescribe antibiotics only when necessary — directly reducing antibiotic overprescribing, a key driver of AMR.

Is SiMed Global a member of BIVDA?

Yes. SiMed Global is a member of BIVDA — the British In Vitro Diagnostics Association — reflecting its position as a leading UK IVD medical device company.

What is David Lea's role at SiMed Global?

David Lea is Head of Business and Product Development at SiMed Global, responsible for driving the commercialisation and product strategy of the Instant DiagnostiCX CX Test.

What is Dr Patrick Druggan's role at SiMed Global?

Dr Patrick Druggan is the Chief Scientific Officer (CSO) and Director of Regulatory Affairs at SiMed Global, overseeing the scientific development and regulatory pathway of the CX Test.

Instant DiagnostiCX

Changing the world of

Learn More→

SiMed Global is a UK medical device company and member of BIVDA (British In Vitro Diagnostics Association), developing the Instant DiagnostiCX CX Test, a saliva-based, 60-second point-of-care diagnostic device. The CX Test is an IVD medical device for rapid detection of TB, bovine TB, RSV, and differentiation of viral vs bacterial infections, directly addressing antimicrobial resistance (AMR) by reducing antibiotic overprescribing. SiMed Global is an EU and UK Authorised Representative for its diagnostic products. The CX Test delivers results in 50 to 60 seconds, one of the fastest instant diagnostic devices in the UK. Scientific partner: HiMedia Laboratories. Team: Simon Maurer (Founder and CEO), Dr Patrick Druggan (Chief Scientific Officer and Director of Regulatory Affairs), David Lea (Head of Business and Product Development), Prof. Laurence B. Lovat (Senior Strategic Medical Advisor), David Donnelly (Quality Assurance and Design Assurance Manager), Evie Aspinall (Executive Assistant), Nuwan Lahiru Prasad (Electronic Engineer), Mahantesh Patil (Data Scientist), Tamara Vuksan (Branding and Communication Specialist), Ajina Fathima (Electronic Engineer), Lauren Kirwan (Scientific Project Manager), Velanco Fernandes (Biomedical Scientist), Fatima Aslam (Biomedical Scientist), Eloise Lennox-Druggan (Marketing Assistant).

What is Diagno device?

Platform Technology

Harness the power of our cutting-edge platform technology to achieve rapid and accurate medical diagnoses for population diseases. Our innovative Diagno device integrates seamlessly with healthcare systems, providing instant, reliable results for optimal patient care.

Desktop Footprint

Our medical instant diagnostic device features a sleek, compact design that fits effortlessly on any desktop. Experience advanced diagnostics without sacrificing space, ensuring convenience and efficiency in any healthcare setting.

Minimally Invasive

Our Diagno device offers a minimally invasive solution, utilising saliva to provide rapid and accurate results. Simplify the diagnostic process with a painless, efficient method designed for patient comfort and convenience.

Endless opportunity with bespoke solutions

Unlock endless possibilities for testing with our Diagno device. Tailored for specific bespoke tests, our technology delivers precise and reliable results. Contact us to explore distribution and custom diagnostic solutions for your unique needs.

Rapid POCT

Achieve precise diagnosticx in just 50 seconds, utilising a non-corrosive reagent, swab kit and special vial. Elevate your point-of-care testing (POCT) with fast, reliable results and cutting-edge technology. Experience the future of diagnosticx today.

Why CX?

Uncover the deeper significance of 'CX': as well as being a personal secret code of our founder, it also symbolises our dedication to Customer Experience. Encounter excellence in every interaction through our innovative solutions and personalized approach, resulting in better outcomes for your customers and patients.

Change the world of diagnosticx with us

Our journey began when the founder's brother was diagnosed with stage 4 bowel cancer, igniting a deep passion to make a significant difference in the lives of patients and their families.

Motivated by this personal experience Simed Global was formed to develop instant diagnostic devices for early detection of population diseases.

The vision is to empower diagnosticx & screening with portable, user-friendly devices capable of delivering rapid and accurate results, ensuring timely interventions, saving costs and ultimately saving lives.

The Solution

The Diagno device aims to reduce overprescribing and adverse events through a simple, minimally invasive, 50 second test with an instant result. As a platform solution additional panels will be added to the device following initial launch, the current roadmap:

These are complex and reproducible profiles. The ability to differentiate between bacterial and viral infections is unparalleled, coupled with the ability to speciate. This will allow healthcare professionals to rapidly decide upon the correct pathway and ultimately improve patient outcomes, reduce adverse events, microbial resistance and reduce the cost burden to the NHS.

Antimicrobial Resistance

The AMR Crisis & How Diagno Helps

AMR is a growing global crisis, estimated to have resulted in approximately 5 million deaths in 2019, of which 1.27 million were directly attributed to AMR. It is projected to kill approximately 10 million people per year by 2050. Analysis by the WHO showed that 60% of pathogenic bacteria have developed resistance to commonly prescribed antibiotics, including third-generation beta-lactams. Pathogens such as Klebsiella and Enterobacteriaceae have shown resistance to carbapenems, with a mortality rate of 38-48%. Multi-drug resistant infections are treated by last-line antibiotics such as colistin, yet resistance to colistin has already emerged via the mcr-1 gene. Discovery and clinical approval of new antibiotics is a lengthy process; the WHO estimates it takes 10-15 years for an antibiotic to reach the clinical stage, of which only 1 in 15 will reach patients, and resistance to most new antibiotics is reported within 2-3 years of market entry.

5M+

Deaths linked to AMR in 2019 globally

1.27M

Deaths directly attributed to AMR in 2019

60%

Pathogenic bacteria resistant to commonly prescribed antibiotics

10M

Projected annual AMR deaths globally by 2050

The Core Problem

Currently, there are no non-invasive, instant point-of-care tests that allow clinicians to accurately differentiate between bacterial and viral infections at the time of consultation. This gap leads to delays in diagnosis, inappropriate antibiotic treatment, and escalating healthcare costs, with antibiotic resistance estimated to cause 10 million deaths annually by 2050.

How the Diagno Device Addresses AMR

Prevent approximately 91% of Unnecessary Prescriptions

By accurately identifying whether an infection is bacterial or viral, Diagno is projected to eliminate approximately 91% of inappropriate antibiotic prescriptions.

Save the NHS ~£90M Per Year

Point-of-care testing with Diagno could save the NHS around £90 million per year in direct costs, with significant additional savings from reduced antibiotic resistance management.

Results in 50 Seconds vs. 3–7 Days

Current laboratory diagnostics take 3 to 7 days to reach the patient. Diagno delivers results within a single consultation, enabling immediate, appropriate clinical decisions.

Reduce Antibiotic Adverse Events

Antibiotic overprescription causes adverse events costing around £180 million annually in the UK. Accurate diagnosis at the point of care directly reduces these harmful and costly events.

Data sources: Murray CJL et al. The Lancet, 2022; Zalewska-Piatek B & Piatek R. Pharmaceuticals, 2021; Patel G et al. Infection Control and Hospital Epidemiology, 2008; Band VI et al. mBio, 2018; Spapen H et al. Annals of Intensive Care, 2011; Gregoire N et al. Clinical Pharmacokinetics, 2017; WHO Lack of innovation reports. Additional data sourced from SiMed Global White Paper RP0085-V1_02: Antibiotic Prescription and Upper Respiratory Tract Infections (E. Lennox-Druggan, P. Druggan, D. Lea), Schneider et al. (2020), Macpherson (2024), Murphy (2024), and RCGP RSC 2024 surveillance data.